Moleculin Announces 2023 Year-End Annamycin Clinical Trials Preliminary Data and 2024 Expectations for Multiple Data Readouts and Transition to Pivotal Phase 2B/3
Stock Information for Moleculin Biotech Inc.
Loading
Please wait while we load your information from QuoteMedia.